Zobrazeno 1 - 6
of 6
pro vyhledávání: '"D A M, Heideman"'
Autor:
A J van der Wekken, J L Kuiper, A Saber, M M Terpstra, J Wei, T J N Hiltermann, E Thunnissen, D A M Heideman, W Timens, E Schuuring, K Kok, E F Smit, A van den Berg, H J M Groen
Publikováno v:
PLoS ONE, Vol 12, Iss 8, p e0182885 (2017)
To determine survival in afatinib-treated patients after treatment with first-generation EGFR tyrosine kinase inhibitors (TKIs) and to study resistance mechanisms in afatinib-resistant tumors.Characteristics and survival of patients treated with afat
Externí odkaz:
https://doaj.org/article/93cb6fbdcf78436f94adb5f3693dd368
Autor:
D. Kramer, F. B. Thunnissen, M. I. Gallegos-Ruiz, E. F. Smit, P. E. Postmus, C. J. L. M. Meijer, P.J.F. Snijders, D. A. M. Heideman
Publikováno v:
Cellular Oncology, Vol 31, Iss 3, Pp 161-167 (2009)
Background: Increasing evidence points to a negative correlation between K-ras mutations and patient’s response to, or survival benefit after, treatment with EGFR-inhibitors. Therefore, rapid and reliable assays for mutational analysis of the K-ras
Externí odkaz:
https://doaj.org/article/b3dca800acbe4d7e9877d48b2e718323
Autor:
D. A. M. Heideman, F. B. Thunnissen, M. Doeleman, D. Kramer, H. M. Verheul, E. F. Smit, P. E. Postmus, C. J. L. M. Meijer, G.A. Meijer, P. J. F. Snijders
Publikováno v:
Cellular Oncology, Vol 31, Iss 5, Pp 329-333 (2009)
Background: Increasing data from clinical trials support EGFR and K-ras mutation status as predictive markers of tumour response to EGFR-targeted therapies. Consequently, rapid and reliable mutation screening assays are demanded to guide rational use
Externí odkaz:
https://doaj.org/article/0ea96d7979ce4bb1a0a7eaa416f018b2
Autor:
M M, Rietbergen, A A J D, van Bokhoven, B I, Lissenberg-Witte, D A M, Heideman, C R, Leemans, R H, Brakenhoff, E, Bloemena
Publikováno v:
International journal of cancer. 143(2)
Human papillomavirus (HPV)-induced oropharyngeal squamous cell carcinoma (OPSCC) remains increasing worldwide. We aimed to investigate if the HPV-prevalence of OPSCC in the Netherlands is rising as well, also in female patients. In addition, we evalu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dc6924e3caf31a369ba3780c9b8b16cd
https://pubmed.ncbi.nlm.nih.gov/29441569
https://pubmed.ncbi.nlm.nih.gov/29441569
Autor:
E M V, de Cuba, P, Snaebjornsson, D A M, Heideman, N C T, van Grieken, L J W, Bosch, R J A, Fijneman, E, Belt, H, Bril, H B A C, Stockmann, E, Hooijberg, C J A, Punt, M, Koopman, I D, Nagtegaal, V H M, Coupé, B, Carvalho, G A, Meijer
Publikováno v:
International journal of cancer. 138(5)
Microsatellite instability (MSI) has been associated with favourable survival in early stage colorectal cancer (CRC) compared to microsatellite stable (MSS) CRC. The BRAF V600E mutation has been associated with worse survival in MSS CRC. This mutatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dd0c3a1152cbeb3285f6dc6536ff074b
https://pubmed.ncbi.nlm.nih.gov/26376292
https://pubmed.ncbi.nlm.nih.gov/26376292
Autor:
H M, Pinedo, J, Buter, S A, Luykx-de Bakker, P R, Pohlmann, Y, van Hensbergen, D A M, Heideman, P J, van Diest, T D, de Gruijl, E, van der Wall
Publikováno v:
European journal of cancer (Oxford, England : 1990). 39(8)
The effect of long-term administration of granulocyte-macrophage colony-stimulating factor (GM-CSF) on dendritic cell (DC) activation and survival in patients with locally advanced breast cancer (LABC) was studied. To this end, the number of activate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::43bbd529c261e0e4114c472c002e513a
https://pubmed.ncbi.nlm.nih.gov/12736101
https://pubmed.ncbi.nlm.nih.gov/12736101